FTC crackdown, court ruling ignite drug price reform push

In July 2026, the FTC secured a landmark settlement with CVS Caremark that mandated enhanced transparency and affordability measures targeting rebate practices and pharmacy network contracting. CVS Caremark committed to aligning member cost sharing with net medication costs, simplifying pricing structures, and expanding affordability programs such as capping insulin costs at $25 per month and implementing point-of-sale rebates and the TrueCost pricing model, which had already contributed to nearly $80 billion in negotiated drug savings. Beyond legal resolution, the settlement encouraged ongoing innovation, including automated prior authorization and promotion of lower-cost biosimilars, signaling a regulatory approach that blends enforcement with industry-led solutions to curb inflated drug costs.

Shortly after, the FTC’s settlement with Caremark Rx and Zinc Health Services intensified scrutiny on PBM rebate structures, framing them as antitrust concerns that distort competition by incentivizing higher list prices and ultimately inflating patient out-of-pocket costs. This enforcement action marked a strategic shift by the FTC to challenge how PBM incentive models, particularly rebate arrangements, may indirectly harm consumers despite nominal discounts, thereby spotlighting rebate practices as a key target in antitrust regulation of the pharmaceutical supply chain.

The Caremark Rx settlement also signaled a broader regulatory crackdown on PBM contracting and rebate programs, with the FTC emphasizing the need for greater transparency and reassessment of business practices that could be construed as inflating patient costs. This heightened scrutiny is expected to influence not only federal enforcement but also private litigation, state regulatory actions, and class claims, as stakeholders across the healthcare ecosystem—PBMs, manufacturers, and downstream providers—face increased pressure to ensure their rebate and formulary decisions do not undermine affordability or competition.

By August 2026, the FTC’s settlement with Caremark had crystallized into a pivotal moment in antitrust enforcement targeting dominant PBMs, offering early insights into the agency’s evidentiary standards and remedy preferences that extend beyond traditional horizontal competition to include dominant intermediaries. This case, closely tied to ongoing insulin pricing litigation, is poised to set a precedent with wide-reaching implications for state enforcement, civil discovery, and class actions, potentially reshaping PBM contracting and transparency obligations across the pharmaceutical sector long after the case’s closure.

By mid-2026, pharmacy benefits had emerged as one of the largest healthcare expenses for employers, yet responsibility for managing these costs was frustratingly fragmented across HR, finance, brokers, consultants, and PBMs. This diffusion of accountability meant that no single entity owned the challenge of controlling pharmacy spend or improving outcomes, leading many employers to react superficially by switching vendors or shifting costs onto employees rather than tackling underlying inefficiencies.

Despite the pharmacy benefits market being dominated by a handful of large PBMs controlling most prescription claims, this concentration of market power did not translate into strategic governance or effective oversight. Unlike other major spend categories where clear ownership and operational accountability drive cost control, pharmacy benefits remained a murky arena lacking measurable expectations and cohesive management, perpetuating inefficiencies and unchecked cost growth.

Closing the accountability gap requires employers to decisively establish clear ownership of pharmacy benefits, set measurable performance expectations, and enforce operational accountability. This strategic shift is essential not only to better control pharmacy spend but also to enhance the employee experience and incentivize improved health outcomes, transforming pharmacy benefits from a fragmented cost center into a well-governed asset.

In a pivotal 4–3 ruling on August 3, 2026, the Michigan Supreme Court restored Attorney General Dana Nessel’s authority to investigate Eli Lilly’s insulin pricing under the Michigan Consumer Protection Act (MCPA), overturning earlier decisions that had shielded regulated industries from such scrutiny. This legal reversal not only revives the probe into allegations that Eli Lilly’s insulin prices have driven average out-of-pocket costs to nearly $100 per vial but also marks a significant shift in how consumer protection laws apply to pharmaceutical pricing within regulated sectors. By reaffirming the MCPA’s reach, the court has reopened the door for more robust legal challenges against drug pricing practices in Michigan, signaling a potential increase in accountability for pharmaceutical companies.

Beyond the immediate Eli Lilly case, the Michigan Supreme Court’s decision clarifies the broader applicability of consumer protection laws to regulated industries, a domain previously considered somewhat insulated from such claims. This clarification could catalyze a wave of new lawsuits targeting not only pharmaceutical pricing but also other consumer issues within regulated sectors, reshaping the legal landscape for corporate accountability in Michigan. The ruling thus serves as a landmark precedent, potentially empowering state regulators and consumers alike to challenge pricing abuses that have long been difficult to contest under existing regulatory frameworks.